Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
McKinsey
Moodys
AstraZeneca
Colorcon

Last Updated: May 19, 2022

CLINICAL TRIALS PROFILE FOR ELTROMBOPAG OLAMINE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Eltrombopag Olamine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00351468 ↗ EXTEND (Eltrombopag Extended Dosing Study) Completed Novartis Phase 3 2006-06-01 An open-label, dose-adjustment, extension study to evaluate the safety and efficacy of eltrombopag for the treatment of subjects with idiopathic thrombocytopenic purpura (ITP) who have previously been enrolled in an eltrombopag trial. This study will allow adjustment of the eltrombopag dose to achieve an individualized dose and schedule for each subject. In addition, the ability to reduce the dose of concomitant ITP medications in the presence of eltrombopag, while maintaining platelet counts = 50,000/μL will be investigated.
NCT00351468 ↗ EXTEND (Eltrombopag Extended Dosing Study) Completed Novartis Pharmaceuticals Phase 3 2006-06-01 An open-label, dose-adjustment, extension study to evaluate the safety and efficacy of eltrombopag for the treatment of subjects with idiopathic thrombocytopenic purpura (ITP) who have previously been enrolled in an eltrombopag trial. This study will allow adjustment of the eltrombopag dose to achieve an individualized dose and schedule for each subject. In addition, the ability to reduce the dose of concomitant ITP medications in the presence of eltrombopag, while maintaining platelet counts = 50,000/μL will be investigated.
NCT00370331 ↗ RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag Completed GlaxoSmithKline Phase 3 2006-11-01 The rationale for this Phase III study is to evaluate the 6 month safety and efficacy of eltrombopag in the treatment of previously treated subjects with chronic ITP. The starting dose of eltrombopag, 50 mg, once daily was selected based upon the observed efficacy, safety and pharmacokinetics in a dose-finding Study (TRA100773). This Phase III study is a randomized, double-blind, placebo-controlled, Phase III study, to evaluate efficacy, safety and tolerability of eltrombopag, initially administered as 50 mg oral tablets once daily for six months in adult subjects with previously treated chronic ITP. Subjects will be randomized 2:1, eltrombopag to placebo, and will be stratified based upon splenectomy status, use of ITP medication at baseline and baseline platelet count less than or equal to 15,000/µL. Subjects will receive study medication for 6 months, during which the dose of study medication may be adjusted based upon individual platelet counts. In addition, subjects may taper off concomitant ITP medications and may receive any rescue treatments as dictated by local standard of care. After discontinuation of study medication, subjects will complete follow-up visits at weeks 1, 2, 4 and months 3 and 6.
NCT00424177 ↗ Repeated Exposure to Eltrombopag in Adults With Idiopathic Thrombocytopenic Purpura (REPEAT) Completed GlaxoSmithKline Phase 2 2007-03-01 This open-label, repeat dosing study, TRA108057, will evaluate the efficacy, safety and tolerability of eltrombopag, when administered in a repeat, cyclic dosing schedule. The study will describe the effect of repeated (3 cycles), intermittent dosing of eltrombopag on the pharmacodynamics and durability of eltrombopag response as measured by the peripheral platelet counts. For more information or to see if you qualify, please visit: http://www.itpstudy.com/gov
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Eltrombopag Olamine

Condition Name

Condition Name for Eltrombopag Olamine
Intervention Trials
Purpura, Thrombocytopaenic, Idiopathic 5
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) 2
Adult Acute Minimally Differentiated Myeloid Leukemia (M0) 2
Adult Acute Myelomonocytic Leukemia (M4) 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Eltrombopag Olamine
Intervention Trials
Purpura, Thrombocytopenic, Idiopathic 6
Purpura, Thrombocytopenic 6
Purpura 6
Thrombocytopenia 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Eltrombopag Olamine

Trials by Country

Trials by Country for Eltrombopag Olamine
Location Trials
United States 90
Germany 34
Italy 31
Canada 16
United Kingdom 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Eltrombopag Olamine
Location Trials
New York 8
Georgia 6
Texas 6
Virginia 5
Missouri 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Eltrombopag Olamine

Clinical Trial Phase

Clinical Trial Phase for Eltrombopag Olamine
Clinical Trial Phase Trials
Phase 4 1
Phase 3 3
Phase 2/Phase 3 1
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Eltrombopag Olamine
Clinical Trial Phase Trials
Completed 9
Active, not recruiting 3
Terminated 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Eltrombopag Olamine

Sponsor Name

Sponsor Name for Eltrombopag Olamine
Sponsor Trials
GlaxoSmithKline 7
National Cancer Institute (NCI) 5
Novartis Pharmaceuticals 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Eltrombopag Olamine
Sponsor Trials
Industry 13
Other 7
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Baxter
Express Scripts
Harvard Business School
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.